MaxiVAX is a Swiss clinical-stage biotechnology company which, having completed a first-in-man Phase I clinical study, is now planning to perform several Phase II multicenter studies in different types of cancer.
First generation cancer immunotherapies are paving the way for MaxiVAX’s personalized immunotherapy.
A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer.
Rue de l'Athénée 24
+41 22 552 26 13